K

Kyowa Kirin

Global specialty pharma focused on antibodies

Rare Disease Senior Medical Science Liaison

Full-TimeUpdated on 10/23/2026
$195.1k - $215k+ Annual bonus program + 401(k) company match + Long-term incentive program
Senior
Bachelor's, Master's, PharmD, PhD, MD
Dallas, TX, USA
In Person
Medical, Clinical & Veterinary

About the job

Requirements
  • An advanced clinical or scientific degree or healthcare professional credential (for example, MD, DO, PhD, PharmD, NP, PA, MS, or equivalent) is required.
  • A minimum of 5 years of Medical Science Liaison experience within the pharmaceutical industry is required.
  • Candidates should understand assigned disease states, therapeutic landscapes, treatment guidelines, current standards of care, and emerging scientific trends.
  • Candidates must demonstrate the ability to influence Medical Affairs strategy and organizational decision-making through scientific engagement, actionable field insights, and leadership of strategic initiatives.
  • Candidates should understand clinical research methodology, evidence-generation strategies, and interpretation of clinical trial data.
  • Candidates should have working knowledge of FDA regulations, Good Clinical Practice, pharmacovigilance requirements, Office of Inspector General guidance, and applicable industry standards.
  • Candidates must be able to evaluate medical literature, synthesize scientific information, and translate complex data into insights and recommendations for healthcare professionals and internal stakeholders.
  • Candidates must be skilled in delivering accurate, balanced, and compliant scientific presentations to external and internal audiences.
  • Candidates should be able to analyze medical insights, identify emerging trends, and inform data-driven decision-making within Medical Affairs.
  • Candidates must be able to manage multiple priorities, organize field-based activities, and work effectively in a cross-functional environment.
  • Candidates should demonstrate strategic thinking, problem-solving, and decision-making skills.
  • Candidates must be able to build working relationships, influence without authority, and manage conflict effectively.
  • Candidates must have written, verbal, listening, facilitation, and presentation skills.
  • Candidates must have experience using Medical Affairs systems and customer relationship management platforms, and proficiency with Microsoft Word, Excel, PowerPoint, and Outlook.
  • Candidates must demonstrate scientific credibility and serve as a trusted scientific resource for internal and external stakeholders.
  • Candidates must be able to establish and maintain strategic relationships with key opinion leaders, healthcare professionals, investigators, and other external stakeholders across a geographically dispersed territory.
  • Candidates should demonstrate collaboration and effective cross-functional partnership.
  • Candidates must be able to prioritize independently, manage competing demands, exercise sound judgment, and adapt to evolving business needs.
  • Candidates should have organizational skills and attention to detail, and be able to work effectively in a field-based environment.
  • Candidates should demonstrate leadership through mentorship, coaching, project leadership, and contributions to strategic initiatives.
  • Candidates must be able to navigate ambiguity and changing priorities while working in a fast-paced environment.
  • Candidates must be committed to ethical, legal, regulatory, and scientific standards and compliant behavior.
  • Candidates should be committed to continuous learning and maintaining therapeutic-area and broader healthcare expertise.
  • Candidates must demonstrate cultural sensitivity and collaborate effectively within diverse and multinational organizations.
  • The role requires the ability to travel frequently, including extended periods of sitting during air, ground, and other transportation; prolonged use of computers and office equipment; and participation in scientific meetings, conferences, advisory boards, and healthcare professional engagements.
  • A valid driver's license and the ability to operate a motor vehicle for business travel are required.
  • The candidate must reside within the assigned territory and maintain proximity to a major airport.
Responsibilities
  • Establish and advance strategic scientific relationships with international, national, regional, and local key opinion leaders, healthcare professionals, investigators, and other external stakeholders.
  • Educate healthcare professionals and other appropriate stakeholders about company scientific data, disease states, therapeutic landscapes, emerging clinical evidence, and the product portfolio.
  • Provide accurate, transparent, fair-balanced, evidence-based, and compliant scientific and clinical information, including responses to unsolicited medical information requests.
  • Serve as a regional medical and scientific resource by identifying stakeholder needs and connecting stakeholders with company capabilities, resources, initiatives, and scientific collaborations.
  • Gather, analyze, synthesize, and communicate actionable medical insights, unmet medical needs, treatment trends, and competitive intelligence, including strategic implications and recommended actions for Medical Affairs and cross-functional stakeholders.
  • Develop and deliver scientific presentations, educational programs, clinical resources, and other materials in response to stakeholder needs and appropriate requests.
  • Liaise independently between investigators and the company regarding unsolicited investigator-initiated study proposals and ongoing studies in accordance with company policies and regulatory requirements.
  • Partner with Clinical Operations and other internal stakeholders to support company-sponsored clinical studies, as appropriate.
  • Support speaker identification, development, training, and ongoing scientific education initiatives, as appropriate.
  • Lead planning and execution of field medical activities and provide scientific support at medical congresses, advisory boards, investigator meetings, and other scientific forums.
  • Deliver scientific education and training to internal cross-functional partners on disease states, therapeutic landscapes, clinical data, emerging evidence, and company products.
  • Build cross-functional partnerships across Medical Affairs, Clinical Development, Clinical Operations, Commercial, Market Access, Regulatory Affairs, and other functions while maintaining appropriate boundaries between scientific and commercial activities.
  • Communicate and disseminate important product safety information to healthcare professionals in accordance with applicable internal requirements and policies.
  • Maintain scientific expertise through continuous review of clinical literature, treatment guidelines, emerging evidence, and developments in the assigned therapeutic area and competitive landscape.
  • Participate in promotional and medical review committee activities, as required.
  • Ensure adherence to applicable laws, regulations, industry codes, and company regulatory, legal, compliance, pharmacovigilance, and privacy policies.
  • Mentor and serve as a scientific resource to other Medical Science Liaisons by sharing expertise, field insights, and best practices, as appropriate.
  • Lead or contribute to cross-functional initiatives, Medical Affairs priorities, strategic planning, and special projects, translating field insights and scientific evidence into actionable perspectives.
  • Develop and execute a strategic territory plan using stakeholder, scientific, and field insights to prioritize engagements and optimize medical impact; exercise sound judgment, adaptability, and effective prioritization of resources and activities.
  • Travel by air and ground transportation for regional coverage, including overnight travel and occasional weekend commitments to support scientific congresses, advisory boards, and other Medical Affairs activities.
Desired Qualifications
  • A doctoral degree (MD, DO, PhD, or PharmD) is preferred.
  • Experience supporting Rare Disease, Endocrinology, Metabolic Bone Disease, Nephrology, Rheumatology, or related therapeutic areas is strongly preferred.

About the company

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for its PreCheck Pilot Program on June 30, 2026.
  • Kyowa Kirin signed a U.S. access deal August 31, 2026, deferring Section 232 tariffs.
  • Pipeline remains active: KHK4951, OTL-203, and ziftomenib all advanced in 2026.

What critics are saying

  • Rocatinlimab died March 3, 2026 after Kaposi's sarcoma signals and trial termination.
  • Kyowa Kirin faces patent cliffs: major products lose protection in 2032 and 2033.
  • Sanford's $530 million build concentrates execution risk until FDA-ready production starts in 2027.

What makes Kyowa Kirin unique

  • Kyowa Kirin owns antibody, fermentation, and rare-disease manufacturing expertise since 1949.
  • The Sanford, North Carolina plant becomes its first U.S. biologics site, operational 2027.
  • Ziftomenib outside the U.S. gives Kyowa Kirin global AML rights through 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Hybrid Work Options
  • Pet Insurance

Growth & Insights and Company News

6 month growth

-2%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

PR Newswire
Dec 15th, 2025
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

/PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A...

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding